Trial reportInternational ophthalmology
Short-term effect of dipyridamole on blood flow velocities in the extraocular vessels.
Trial report in International ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Updates on Intrinsic Medicinal Chemistry of 1,4-dihydropyridines, Perspectives on Synthesis and Pharmacokinetics of Novel 1,4-dihydropyrimidines as Calcium Channel Blockers: Clinical Pharmacology.Current topics in medicinal chemistry · 2025Review
- Bicyclic 6 + 6 systems: the chemistry of pyrimido[4,5-RSC advances · 2019Review
- The discovery of the Flammer syndrome: a historical and personal perspective.The EPMA journal · 2017Review
- Ocular Applications of Dipyridamole: A Review of Indications and Routes of Administration.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2016Review
- Pterygium: nonsurgical treatment using topical dipyridamole - a case report.Case reports in ophthalmology · 2014Article
- The Role of Magnesium in the Pathogenesis and Treatment of Glaucoma.International scholarly research notices · 2014Review
- The primary vascular dysregulation syndrome: implications for eye diseases.The EPMA journal · 2013Article
- Targeted preventive measures and advanced approaches in personalised treatment of glaucoma neuropathy.The EPMA journal · 2010Article
- Circulating platelet aggregates in glaucoma.International ophthalmologyArticle
- Why study vascular factors in glaucoma?International ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dipyridamole is known to inhibit platelet aggregation and to induce vasodilatation. It has been shown that dipyridamole increases blood flow in various tissues in humans as well as in the eyes of animals. We studied the influence of dipyridamole in a prospective open trial in 23 patients with impaired ocular circulation due to different causes, based on experienced clinical judgement, such as anterior ischemic optic neuropathy, vasospastic syndrome, glaucoma, or central retinal vein occlusion. Blood flow velocities in the ophthalmic artery, central retinal artery and vein, one lateral and one medical posterior ciliary artery were measured using a Siemens Quantum 2000 color Doppler device. Blood flow velocities were measured before and under treatment. Dipyridamole increased blood flow velocities significantly in all vessels measured. Therefore, it seems promising to evaluate the effect of dipyridamole over a longer period in patients with impaired ocular blood flow.
Indexed as
Identifiers
8970869What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.